Dr Roger Thompson MB ChB BSc MRCP(UK) PhD

BHF Intermediate Clinical Fellow and Honorary Respiratory Consultant

Department of Infection, Immunity and Cardiovascular Disease
University of Sheffield
Medical School
Beech Hill Road
Sheffield
S10 2RX
United Kingdom

Tel: +44 (0)114 215 9558
Fax: +44 (0)114 271 1863
Email: r.thompson@sheffield.ac.uk

Biography:

I moved to Sheffield in 2006 to take up an NIHR Academic Clinical Fellowship in Respiratory Medicine having completed my undergraduate training and a medical rotation in Edinburgh. I completed an MRC Training Fellowship and PhD in 2012 under the supervision of Professor Moira Whyte and Dr Sarah Walmsley before finishing my specialist clinical training as an NIHR Clinical Lecturer. In 2016, I was appointed as a JG Graves Fellow and an Honorary Consultant in Respiratory Medicine at Sheffield Teaching Hospitals NHS Foundation Trust. For 12 months from September 2017 I was a BHF-Fulbright scholar (www.fulbright.org.uk) in Professor Marlene Rabinovitch’s lab at Stanford University. Now back in Sheffield I will continue my research as a BHF Intermediate Clinical Fellow.

Research Interests:

Hypoxia has been the general theme of my research interests. In 2001 and 2003 I organised two successful high altitude research expeditions to Bolivia, focusing on maladaptive responses to hypoxia that can result in altitude illness (www.altitude.org). I hope to translate this interest in altitude hypoxia into understanding how the body responds to hypoxia in the context of respiratory disease at sea level. During my PhD, I broadened my interests into the field of cell biology, specifically the role of HIF-2alpha in neutrophilic inflammation. I also worked on host pathogen interactions in hypoxia, a project for which I was awarded an Academy of Medical Sciences Starter Grant. Now I aim to align my research interests with my clinical interest in pulmonary hypertension using my background in pulmonary inflammation and hypoxia to provide new perspectives on this disease.

Pulmonary arterial hypertension (PAH) is a devastating condition characterised by progressive remodelling of pulmonary blood vessels leading to right heart failure and death. The pattern recognition receptor, Toll-like receptor 3 (TLR3) is critically involved in the recognition of viral pathogens and emerging evidence suggests it regulates vascular remodelling. I have generated novel unpublished data implicating double-stranded RNA (dsRNA), a TLR3 ligand, in the pathogenesis of PAH. I aim to dissect the mechanism by which dsRNA regulates PAH and to assess the therapeutic impact of activating dsRNA signalling pathways in PAH models.

Current Projects:

Hypoxic modulation of host responses to infection.
Regulation of pulmonary vascular remodelling by endogenous double stranded RNA.

Publications:

For key publications see below. For a full list of publications click here.

Journal articles

Farkas D, Thompson AAR, Bhagwani AR, Hultman S, Ji H, Kotha N, Farr G, Arnold ND, Braithwaite A, Casbolt H, Cole JE, Sabroe I, Monaco C, Cool CD, Goncharova EA, Lawrie A & Farkas L (2018) Toll-like receptor 3 is a therapeutic target for pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine. View this article in WRRO
Quadery SR, Swift AJ, Billings C, Thompson AAR, Elliot CA, Hurdman J, Charalampopoulos A, Sabroe I, Armstrong I, Hamilton N, Sephton P, Garrod S, Pepke-Zaba J, Jenkins DP, Screaton N, Rothman AM, Lawrie A, Cleveland T, Thomas S, Rajaram S, Hill C, Davies C, Johns CS, Wild JM, Condliffe R & Kiely DG (2018) The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. European Respiratory Journal. View this article in WRRO
Rocke A, Paterson G, Barber M, Jackson A, Main S, Stannett C, Schnopp M, Baillie J, Horne E, Moores C, Harrison P, Nimmo A & Thompson A (2018) Thromboelastometry and Platelet Function during Acclimatization to High Altitude. Thrombosis and Haemostasis, 118(01), 063-071. View this article in WRRO
Renshall L, Arnold N, West L, Braithwaite A, Pickworth J, Walker R, Alfaidi M, Chamberlain J, Casbolt H, Thompson AAR, Holt C, Iglarz M, Francis S & Lawrie A (2017) Selective improvement of pulmonary arterial hypertension with a dual ET A /ET B receptors antagonist in the apolipoprotein E −/− model of PAH and atherosclerosis. Pulmonary Circulation, 8(1). View this article in WRRO
Thompson AAR, Dickinson RS, Murphy F, Thomson JP, Marriott HM, Tavares A, Willson J, Williams L, Lewis A, Mirchandani A, Coelho PDS, Doherty C, Ryan E, Watts E, Morton NM, Forbes S, Stimson RH, Hameed AG, Arnold N, Preston JA, Lawrie A, Finisguerra V, Mazzone M, Sadiku P, Goveia J, Taverna F, Carmeliet P, Foster SJ, Chilvers ER, Cowburn AS, Dockrell DH, Johnson RS, Meehan RR, Whyte MKB & Walmsley SR (2017) Hypoxia determines survival outcomes of bacterial infection through HIF-1α-dependent reprogramming of leukocyte metabolism. Science Immunology, 2(8). View this article in WRRO
Thompson AAR & Lawrie A (2017) Targeting Vascular Remodeling to Treat Pulmonary Arterial Hypertension. Trends in Molecular Medicine, 23(1), 31-45. View this article in WRRO
Lodge KM, Thompson AAR, Chilvers ER & Condliffe AM (2016) Hypoxic regulation of neutrophil function and consequences for Staphylococcus aureus infection. Microbes and Infection. View this article in WRRO
Hickey PM, Thompson AA, Charalampopoulos A, Elliot CA, Hamilton N, Kiely DG, Lawrie A, Sabroe I & Condliffe R (2016) Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension. European Respiratory Journal, 48(5), 1514-1514.
Finisguerra V, Di Conza G, Di Matteo M, Serneels J, Costa S, Thompson AAR, Wauters E, Walmsley S, Prenen H, Granot Z, Casazza A & Mazzone M (2015) MET is required for the recruitment of anti-tumoural neutrophils. Nature, 522(7556), 349-353. View this article in WRRO
Hall DP, MacCormick IJC, Phythian-Adams AT, Rzechorzek NM, Hope-Jones D, Cosens S, Jackson S, Bates MGD, Collier DJ, Hume DA, Freeman T, Thompson AAR & Baillie JK (2014) Network Analysis Reveals Distinct Clinical Syndromes Underlying Acute Mountain Sickness. PLoS ONE, 9(1), e81229-e81229. View this article in WRRO
Thompson AAR, Elks PM, Marriott HM, Eamsamarng S, Higgins KR, Lewis A, Williams L, Parmar S, Shaw G, McGrath EE, Formenti F, Van Eeden FJ, Kinnula VL, Pugh CW, Sabroe I, Dockrell DH, Chilvers ER, Robbins PA, Percy MJ, Simon MC, Johnson RS, Renshaw SA, Whyte MKB & Walmsley SR (2014) Hypoxia-inducible factor 2 regulates key neutrophil functions in humans, mice, and zebrafish. Blood, 123(3), 366-376.
Thompson AA, Binham J, Plant T, Whyte MK & Walmsley SR (2013) Hypoxia, the HIF pathway and neutrophilic inflammatory responses. Biological Chemistry, 394(4), 471-477.
Walmsley SR, Chilvers ER, Thompson AA, Vaughan K, Marriott HM, Parker LC, Shaw G, Parmar S, Schneider M, Sabroe I, Dockrell DH, Milo M, Taylor CT, Johnson RS, Pugh CW, Ratcliffe PJ, Maxwell PH, Carmeliet P & Whyte MKB (2011) Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice. Journal of Clinical Investigation, 121(3), 1053-1063. View this article in WRRO